Biodock vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 42)
Biodock logo

Biodock

EmergingHealthcare

General

AI cloud computing platform for life sciences microscopy images and NGS sequencing data management; $2.1M a16z pre-seed backed YC W21 at $750K ARR serving biotech and academic research labs.

AI VisibilityBeta
Overall Score
C42
Category Rank
#333 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
40
Perplexity
38
Gemini
47

About

Biodock is a San Francisco-based AI cloud computing platform for life sciences research — providing data management, analysis, and collaboration infrastructure specifically designed for biological research data including microscopy images, next-generation sequencing (NGS) outputs, and other large-scale biological datasets that overwhelm general-purpose cloud storage and analytics tools. Founded in 2020 and backed by Andreessen Horowitz in a pre-seed round with $2.1-2.33 million raised, plus notable angel investors from Tiger Global and Flatiron Health, Biodock (YC W21) reached $750,000 in annual revenue as of June 2025.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

42
Overall Score
90
#333
Category Rank
#2
75
AI Consensus
83
stable
Trend
stable
40
ChatGPT
92
38
Perplexity
93
47
Gemini
89
38
Claude
96
37
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.